Journal Logo

CE Connection

New Drugs 2017, part 3

Author Information
doi: 10.1097/01.NURSE.0000526936.68748.e3
  • Free

INSTRUCTIONS New Drugs 2017, part 3

TEST INSTRUCTIONS

  • To take the test online, go to our secure website at www.nursingcenter.com/ce/nursing.
  • On the print form, record your answers in the test answer section of the CE enrollment form on page 33. Each question has only one correct answer. You may make copies of these forms. A passing score for this test is 13 correct answers.
  • Complete the registration information and course evaluation. Mail the completed form and registration fee of $17.95 to: Lippincott Professional Development, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
  • You will receive your CE certificate of earned contact hours and an answer key to review your results.
  • Registration deadline is November 30, 2019.

DISCOUNTS and CUSTOMER SERVICE

  • Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together by mail, and deduct $0.95 from the price of each test.
  • We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.

PROVIDER ACCREDITATION

Lippincott Professional Development will award 1.5 contact hours for this continuing nursing education activity.

Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia, Georgia, and Florida CE Broker #50-1223. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours.

This activity has been assigned 1.5 pharmacology credits.

New Drugs 2017, part 3

GENERAL PURPOSE: To provide an overview of 11 drugs recently approved by the FDA. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Identify indications for the 11 new drugs. 2. List major adverse reactions associated with select new drugs. 3. Discuss nursing considerations for the new drugs.

  1. Eteplirsen has been approved
    1. to treat spinal muscular atrophy.
    2. despite a lack of established clinical benefit.
    3. to treat adults only.
  2. Eteplirsen should be infused over
    1. 10 to 20 minutes.
    2. 35 to 60 minutes.
    3. 90 to 120 minutes.
  3. Which statement is correct about eteplirsen?
    1. Store the vials at room temperature.
    2. Dilute the drug in 5% Dextrose Injection.
    3. Invert the vials before dilution.
  4. Advise patients receiving eteplirsen about which adverse reaction?
    1. vomiting
    2. facial flushing
    3. lower respiratory tract infection
  5. Nusinersen is administered
    1. I.V.
    2. orally.
    3. intrathecally.
  6. Which test is not required before each dose of nusinersen?
    1. platelet count
    2. ALP
    3. urine protein
  7. Before administration, nusinersen should be
    1. warmed in a microwave.
    2. inspected for particulates and discoloration.
    3. diluted in 100 mL 0.9% Sodium Chloride Injection.
  8. The primary benefit of selexipag is
    1. decreased mortality.
    2. improved exercise capacity.
    3. reduction in hospitalizations.
  9. Selexipag should be avoided in patients who
    1. are breastfeeding.
    2. have renal impairment.
    3. are prone to constipation.
  10. Tell patients taking selexipag that
    1. each dose should be taken on an empty stomach.
    2. the dose should be doubled if they miss treatment for 3 days or more.
    3. the tablets shouldn't be crushed or chewed.
  11. Obeticholic acid is contraindicated in patients with
    1. PBC.
    2. complete biliary obstruction.
    3. severe hepatic impairment.
  12. Obeticholic acid may enhance the effect of
    1. warfarin.
    2. metformin.
    3. caffeine.
  13. Which drug may cause severe pruritus as an adverse reaction?
    1. defibrotide sodium
    2. obeticholic acid
    3. nusinersen
  14. Which instruction should be given to patients taking obeticholic acid?
    1. Take it 1 hour before or 2 hours after calcium-containing products.
    2. Take it on an empty stomach.
    3. It may be taken without regard to food.
  15. Which adverse reaction would most likely result from taking defibrotide sodium?
    1. black tarry stool
    2. prolonged QT interval
    3. hypertension
  16. A defibrotide sodium infusion should be
    1. administered within 24 hours when stored at room temperature.
    2. delivered through a 0.2 micron in-line filter.
    3. completed within 30 minutes.
  17. Which statement about obiltoxaximab is accurate?
    1. It's an antibacterial agent indicated to treat inhalational anthrax.
    2. It's available only from the CDC.
    3. It should be given after a dose of diphenhydramine.
  18. Which drug is indicated to treat both metastatic non–small cell lung cancer and metastatic urothelial carcinoma?
    1. rucaparib
    2. atezolizumab
    3. alectinib
Figure
Figure
Wolters Kluwer Health, Inc. All rights reserved